A pilot study of human interferon β gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes

Kazuhiko Matsumoto, Hitomi Kubo, Hiroshi Murata, Hisashi Uhara, Minoru Takata, Shinichi Shibata, Satoshi Yasue, Akihiro Sakakibara, Yasushi Tomita, Toshiro Kageshita, Yutaka Kawakami, Masaaki Mizuno, Jun Yoshida, Toshiaki Saida

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Cationic liposomes containing the human interferon β (HuIFNβ) gene (IAB-1) was used for the clinical trial for glioma patients. HuIFNβ gene therapy showed much higher anti-tumor activity compared with the administration of HuIFNβ protein for melanoma. These results suggest that HuIFNβ gene therapy is an attractive strategy for the treatment of melanoma. Methods: Stage IV or III melanoma patients with cutaneous or subcutaneous metastatic lesions were enrolled in this pilot study. IAB-1 was dissolved by sterile PBS at a concentration of 30 μg DNA/ml and was injected into cutaneous or subcutaneous metastatic nodules three times a week for 2 weeks and the effect on the injected and non-injected metastatic lesions was evaluated. Results: Clinical responses were as follows (five patients): mixed response (MR) and no change in each one patient, and progressive disease in three patients. In the MR patient, the IAB-1 injected lesion disappeared clinically and histopathologically and one-half of IAB-1 non-injected skin metastases were transiently inflamed and mostly regressed. In the responded non-injected lesions of this patient, histopathologically, infiltration of CD4 positive T cells was observed around the melanoma cells in the dermis, which expressed the HLA-Class II antigen. Adverse events due to this gene therapy were not recognized in any of the patients. Conclusions: The efficacy of this gene therapy was generally insufficient; however, some immunological responses were recognized in one patient. No adverse events were observed. HuIFNβ gene therapy could be an attractive strategy for treatment of a variety of malignancies, including melanoma, though some modifications should be required.

Original languageEnglish
Pages (from-to)849-856
Number of pages8
JournalJapanese Journal of Clinical Oncology
Volume38
Issue number12
DOIs
Publication statusPublished - 2008

Fingerprint

Liposomes
Genetic Therapy
Interferons
Melanoma
Skin
Histocompatibility Antigens Class II
Dermis
Glioma
Neoplasms
Clinical Trials
Neoplasm Metastasis
T-Lymphocytes
DNA
Therapeutics
Genes

Keywords

  • Clinical trial
  • Gene therapy
  • Interferon β
  • Malignant melanoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

A pilot study of human interferon β gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes. / Matsumoto, Kazuhiko; Kubo, Hitomi; Murata, Hiroshi; Uhara, Hisashi; Takata, Minoru; Shibata, Shinichi; Yasue, Satoshi; Sakakibara, Akihiro; Tomita, Yasushi; Kageshita, Toshiro; Kawakami, Yutaka; Mizuno, Masaaki; Yoshida, Jun; Saida, Toshiaki.

In: Japanese Journal of Clinical Oncology, Vol. 38, No. 12, 2008, p. 849-856.

Research output: Contribution to journalArticle

Matsumoto, K, Kubo, H, Murata, H, Uhara, H, Takata, M, Shibata, S, Yasue, S, Sakakibara, A, Tomita, Y, Kageshita, T, Kawakami, Y, Mizuno, M, Yoshida, J & Saida, T 2008, 'A pilot study of human interferon β gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes', Japanese Journal of Clinical Oncology, vol. 38, no. 12, pp. 849-856. https://doi.org/10.1093/jjco/hyn114
Matsumoto, Kazuhiko ; Kubo, Hitomi ; Murata, Hiroshi ; Uhara, Hisashi ; Takata, Minoru ; Shibata, Shinichi ; Yasue, Satoshi ; Sakakibara, Akihiro ; Tomita, Yasushi ; Kageshita, Toshiro ; Kawakami, Yutaka ; Mizuno, Masaaki ; Yoshida, Jun ; Saida, Toshiaki. / A pilot study of human interferon β gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes. In: Japanese Journal of Clinical Oncology. 2008 ; Vol. 38, No. 12. pp. 849-856.
@article{198d72ee871b4c0aaab805ff24666f12,
title = "A pilot study of human interferon β gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes",
abstract = "Background: Cationic liposomes containing the human interferon β (HuIFNβ) gene (IAB-1) was used for the clinical trial for glioma patients. HuIFNβ gene therapy showed much higher anti-tumor activity compared with the administration of HuIFNβ protein for melanoma. These results suggest that HuIFNβ gene therapy is an attractive strategy for the treatment of melanoma. Methods: Stage IV or III melanoma patients with cutaneous or subcutaneous metastatic lesions were enrolled in this pilot study. IAB-1 was dissolved by sterile PBS at a concentration of 30 μg DNA/ml and was injected into cutaneous or subcutaneous metastatic nodules three times a week for 2 weeks and the effect on the injected and non-injected metastatic lesions was evaluated. Results: Clinical responses were as follows (five patients): mixed response (MR) and no change in each one patient, and progressive disease in three patients. In the MR patient, the IAB-1 injected lesion disappeared clinically and histopathologically and one-half of IAB-1 non-injected skin metastases were transiently inflamed and mostly regressed. In the responded non-injected lesions of this patient, histopathologically, infiltration of CD4 positive T cells was observed around the melanoma cells in the dermis, which expressed the HLA-Class II antigen. Adverse events due to this gene therapy were not recognized in any of the patients. Conclusions: The efficacy of this gene therapy was generally insufficient; however, some immunological responses were recognized in one patient. No adverse events were observed. HuIFNβ gene therapy could be an attractive strategy for treatment of a variety of malignancies, including melanoma, though some modifications should be required.",
keywords = "Clinical trial, Gene therapy, Interferon β, Malignant melanoma",
author = "Kazuhiko Matsumoto and Hitomi Kubo and Hiroshi Murata and Hisashi Uhara and Minoru Takata and Shinichi Shibata and Satoshi Yasue and Akihiro Sakakibara and Yasushi Tomita and Toshiro Kageshita and Yutaka Kawakami and Masaaki Mizuno and Jun Yoshida and Toshiaki Saida",
year = "2008",
doi = "10.1093/jjco/hyn114",
language = "English",
volume = "38",
pages = "849--856",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - A pilot study of human interferon β gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes

AU - Matsumoto, Kazuhiko

AU - Kubo, Hitomi

AU - Murata, Hiroshi

AU - Uhara, Hisashi

AU - Takata, Minoru

AU - Shibata, Shinichi

AU - Yasue, Satoshi

AU - Sakakibara, Akihiro

AU - Tomita, Yasushi

AU - Kageshita, Toshiro

AU - Kawakami, Yutaka

AU - Mizuno, Masaaki

AU - Yoshida, Jun

AU - Saida, Toshiaki

PY - 2008

Y1 - 2008

N2 - Background: Cationic liposomes containing the human interferon β (HuIFNβ) gene (IAB-1) was used for the clinical trial for glioma patients. HuIFNβ gene therapy showed much higher anti-tumor activity compared with the administration of HuIFNβ protein for melanoma. These results suggest that HuIFNβ gene therapy is an attractive strategy for the treatment of melanoma. Methods: Stage IV or III melanoma patients with cutaneous or subcutaneous metastatic lesions were enrolled in this pilot study. IAB-1 was dissolved by sterile PBS at a concentration of 30 μg DNA/ml and was injected into cutaneous or subcutaneous metastatic nodules three times a week for 2 weeks and the effect on the injected and non-injected metastatic lesions was evaluated. Results: Clinical responses were as follows (five patients): mixed response (MR) and no change in each one patient, and progressive disease in three patients. In the MR patient, the IAB-1 injected lesion disappeared clinically and histopathologically and one-half of IAB-1 non-injected skin metastases were transiently inflamed and mostly regressed. In the responded non-injected lesions of this patient, histopathologically, infiltration of CD4 positive T cells was observed around the melanoma cells in the dermis, which expressed the HLA-Class II antigen. Adverse events due to this gene therapy were not recognized in any of the patients. Conclusions: The efficacy of this gene therapy was generally insufficient; however, some immunological responses were recognized in one patient. No adverse events were observed. HuIFNβ gene therapy could be an attractive strategy for treatment of a variety of malignancies, including melanoma, though some modifications should be required.

AB - Background: Cationic liposomes containing the human interferon β (HuIFNβ) gene (IAB-1) was used for the clinical trial for glioma patients. HuIFNβ gene therapy showed much higher anti-tumor activity compared with the administration of HuIFNβ protein for melanoma. These results suggest that HuIFNβ gene therapy is an attractive strategy for the treatment of melanoma. Methods: Stage IV or III melanoma patients with cutaneous or subcutaneous metastatic lesions were enrolled in this pilot study. IAB-1 was dissolved by sterile PBS at a concentration of 30 μg DNA/ml and was injected into cutaneous or subcutaneous metastatic nodules three times a week for 2 weeks and the effect on the injected and non-injected metastatic lesions was evaluated. Results: Clinical responses were as follows (five patients): mixed response (MR) and no change in each one patient, and progressive disease in three patients. In the MR patient, the IAB-1 injected lesion disappeared clinically and histopathologically and one-half of IAB-1 non-injected skin metastases were transiently inflamed and mostly regressed. In the responded non-injected lesions of this patient, histopathologically, infiltration of CD4 positive T cells was observed around the melanoma cells in the dermis, which expressed the HLA-Class II antigen. Adverse events due to this gene therapy were not recognized in any of the patients. Conclusions: The efficacy of this gene therapy was generally insufficient; however, some immunological responses were recognized in one patient. No adverse events were observed. HuIFNβ gene therapy could be an attractive strategy for treatment of a variety of malignancies, including melanoma, though some modifications should be required.

KW - Clinical trial

KW - Gene therapy

KW - Interferon β

KW - Malignant melanoma

UR - http://www.scopus.com/inward/record.url?scp=57249107928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57249107928&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyn114

DO - 10.1093/jjco/hyn114

M3 - Article

C2 - 18945721

AN - SCOPUS:57249107928

VL - 38

SP - 849

EP - 856

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 12

ER -